Valacyclovir Hydrochloride side effects: what 70,015 FDA adverse event reports show
Drug class
Not stated in label
Who reports
70,015 reports · 69% serious · 5,662 with death outcome · 60% female
Used for
Valacyclovir tablets are a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocom.
What it is
Valacyclovir hydrochloride, USP is the hydrochloride salt of the L ‑valyl ester of the antiviral drug acyclovir. Valacyclovir tablets, USP are for oral administration. Each film-coated tablet .
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,138 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Laryngeal stenosis | 104 | 65.7 53.1–81.2ROR 65.8 · calibrated p 3e-6 ✓ | 53.4 EB05 45.3 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=104 · ♀ 100% (drug 60%) · 72% consumer | not reported in cached trials |
| Dyslalia | 128 | 64.0 52.9–77.4ROR 64.1 · calibrated p 3e-6 ✓ | 52.3 EB05 45.2 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=126 | not reported in cached trials |
| Vocal cord dysfunction | 82 | 58.7 46.3–74.4ROR 58.8 · calibrated p 6e-6 ✓ | 48.6 EB05 40.4 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=82 · ♀ 100% (drug 60%) | not reported in cached trials |
| Genital herpes | 141 | 30.2 25.4–35.9ROR 30.2 · calibrated p 3e-4 ✓ | 27.4 EB05 23.8 · IC025 +4.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=75 | not reported in cached trials |
| Ophthalmic herpes simplex | 50 | 28.5 21.3–38.1ROR 28.5 · calibrated p 4e-4 ✓ | 25.9 EB05 20.4 · IC025 +3.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=47 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Toxic encephalopathy | 417 | 27.6 24.9–30.5ROR 27.7 · calibrated p 4e-4 ✓ | 25.3 EB05 23.3 · IC025 +4.5 3/3 methods agree | Labeled (related wording) related wording | serious n=416 | not reported in cached trials |
| Herpes virus infection | 466 | 26.2 23.8–28.8ROR 26.4 · calibrated p 5e-4 ✓ | 24.1 EB05 22.3 · IC025 +4.4 3/3 methods agree | Likely indication confounding term in indications | serious n=175 · 71% consumer | not reported in cached trials |
| Periorbital pain | 54 | 21.5 16.3–28.4ROR 21.6 · calibrated p 0.002 ✓ | 20.0 EB05 15.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Herpes simplex | 428 | 21.1 19.1–23.3ROR 21.2 · calibrated p 0.002 ✓ | 19.7 EB05 18.2 · IC025 +4.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=244 | not reported in cached trials |
| Klebsiella bacteraemia | 56 | 19.1 14.6–25.1ROR 19.1 · calibrated p 0.003 ✓ | 17.9 EB05 14.3 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=56 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Diffuse large b-cell lymphoma refractory | 54 | 18.4 14.0–24.2ROR 18.4 · calibrated p 0.003 ✓ | 17.3 EB05 13.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=53 · ♀ 100% (drug 60%) · 100% clinician | not reported in cached trials |
| Herpes ophthalmic | 70 | 16.9 13.3–21.5ROR 16.9 · calibrated p 0.005 ✓ | 15.9 EB05 13.0 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=65 | not reported in cached trials |
| Cytokine release syndrome | 956 | 15.8 14.8–16.8ROR 16.0 · calibrated p 0.005 ✓ | 15.0 EB05 14.2 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 16.3 · serious PRR 12.5 · ♀ 37% (drug 60%) · 97% clinician | not reported in cached trials |
| Alpha haemolytic streptococcal infection | 43 | 14.5 10.7–19.6ROR 14.5 · calibrated p 0.010 ✓ | 13.6 EB05 10.4 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=43 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Post herpetic neuralgia | 66 | 14.3 11.2–18.4ROR 14.4 · calibrated p 0.009 ✓ | 13.6 EB05 11.0 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=45 | not reported in cached trials |
| Streptococcal bacteraemia | 49 | 14.3 10.7–19.0ROR 14.3 · calibrated p 0.010 ✓ | 13.4 EB05 10.5 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=49 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Blood immunoglobulin e increased | 105 | 13.4 11.1–16.3ROR 13.5 · calibrated p 0.012 ✓ | 12.8 EB05 10.8 · IC025 +3.3 3/3 methods agree | Lab value / disease marker | serious n=105 · ♀ 100% (drug 60%) | not reported in cached trials |
| Bone demineralisation | 45 | 13.2 9.8–17.8ROR 13.2 · calibrated p 0.013 ✓ | 12.4 EB05 9.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=35 · ♀ 0% (drug 60%) | not reported in cached trials |
| Ophthalmic herpes zoster | 75 | 13.1 10.4–16.5ROR 13.1 · calibrated p 0.013 ✓ | 12.4 EB05 10.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=74 | not reported in cached trials |
| Immune effector cell-associated neurotoxicity syndrome | 224 | 12.4 10.8–14.2ROR 12.4 · calibrated p 0.015 ✓ | 11.9 EB05 10.6 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=224 · ♀ 38% (drug 60%) · 100% clinician | not reported in cached trials |
| Escherichia bacteraemia | 90 | 12.1 9.8–14.9ROR 12.1 · calibrated p 0.017 ✓ | 11.5 EB05 9.6 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=90 · 100% clinician | not reported in cached trials |
| Hepatic cytolysis | 472 | 12.0 10.9–13.1ROR 12.1 · calibrated p 0.017 ✓ | 11.5 EB05 10.7 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 9.6 · serious PRR 9.6 · 100% clinician | not reported in cached trials |
| Febrile bone marrow aplasia | 158 | 11.7 10.0–13.7ROR 11.7 · calibrated p 0.019 ✓ | 11.2 EB05 9.8 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=158 · 100% clinician | not reported in cached trials |
| Eyelid pain | 72 | 11.5 9.1–14.6ROR 11.5 · calibrated p 0.021 ✓ | 10.9 EB05 8.9 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | ♀ 81% (drug 60%) · 100% consumer | not reported in cached trials |
| Chronic sinusitis | 137 | 11.3 9.6–13.4ROR 11.3 · calibrated p 0.021 ✓ | 10.8 EB05 9.4 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=135 · ♀ 100% (drug 60%) | not reported in cached trials |
| Oral herpes | 651 | 10.3 9.6–11.2ROR 10.4 · calibrated p 0.028 ✓ | 10.0 EB05 9.4 · IC025 +3.2 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 9.0 · serious PRR 9.6 · ♀ 87% (drug 60%) | not reported in cached trials |
| Febrile neutropenia | 2,176 | 10.1 9.7–10.6ROR 10.4 · calibrated p 0.028 ✓ | 9.8 EB05 9.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 10.9 · serious PRR 8.2 · 93% clinician | not reported in cached trials |
| Aplastic anaemia | 172 | 10.1 8.7–11.8ROR 10.1 · calibrated p 0.032 ✓ | 9.7 EB05 8.5 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=172 · ♀ 36% (drug 60%) · 90% clinician | not reported in cached trials |
| Immunoglobulins decreased | 44 | 9.9 7.4–13.4ROR 9.9 · calibrated p 0.037 ✓ | 9.2 EB05 7.0 · IC025 +2.6 3/3 methods agree | Lab value / disease marker | serious n=41 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Altered state of consciousness | 662 | 9.5 8.8–10.2ROR 9.5 · calibrated p 0.038 ✓ | 9.2 EB05 8.6 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 6.7 · serious PRR 7.7 | not reported in cached trials |
| Parainfluenzae virus infection | 47 | 9.3 7.0–12.5ROR 9.3 · calibrated p 0.045 ✓ | 8.6 EB05 6.7 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=47 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Graft versus host disease in gastrointestinal tract | 64 | 9.2 7.2–11.9ROR 9.3 · calibrated p 0.045 ✓ | 8.7 EB05 7.0 · IC025 +2.7 3/3 methods agree | Labeled (related wording) related wording | serious n=64 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Blood pressure diastolic abnormal | 76 | 9.1 7.2–11.4ROR 9.1 · calibrated p 0.047 ✓ | 8.6 EB05 7.0 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | serious n=76 · 100% clinician | not reported in cached trials |
| Neurotoxicity | 506 | 9.0 8.2–9.8ROR 9.0 · calibrated p 0.046 ✓ | 8.7 EB05 8.1 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 9.2 · serious PRR 7.3 · 100% clinician | not reported in cached trials |
| Aplasia | 58 | 8.9 6.9–11.6ROR 8.9 · calibrated p 0.051 | 8.3 EB05 6.6 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=58 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Mixed liver injury | 84 | 8.9 7.1–11.0ROR 8.9 · calibrated p 0.051 | 8.4 EB05 6.9 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=84 · 100% clinician | not reported in cached trials |
| Rhinovirus infection | 101 | 8.1 6.7–9.9ROR 8.2 · calibrated p 0.065 | 7.7 EB05 6.5 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=98 · ♀ 38% (drug 60%) | not reported in cached trials |
| Blood pressure systolic abnormal | 65 | 8.0 6.3–10.2ROR 8.0 · calibrated p 0.070 | 7.5 EB05 6.1 · IC025 +2.5 3/3 methods agree | Lab value / disease marker | serious n=65 · ♀ 100% (drug 60%) · 100% clinician | not reported in cached trials |
| Dermatitis exfoliative generalised | 87 | 7.7 6.3–9.6ROR 7.8 · calibrated p 0.076 | 7.3 EB05 6.1 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=87 · ♀ 0% (drug 60%) · 100% clinician | not reported in cached trials |
| Herpes zoster (shingles) | 1,449 | 7.7 7.3–8.1ROR 7.8 · calibrated p 0.071 | 7.5 EB05 7.2 · IC025 +2.8 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 6.6 · serious PRR 6.8 | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Neutropenia / agranulocytosis | 4,434 | 5.45.3–5.6 | signal |
| Opportunistic infection | 2,067 | 4.64.4–4.8 | signal |
| Severe cutaneous reaction | 880 | 3.63.3–3.8 | signal |
| Thrombocytopenia | 2,268 | 3.13.0–3.2 | signal |
| Kidney injury | 3,859 | 2.52.5–2.6 | signal |
| Serious infection | 5,409 | 2.12.1–2.2 | signal |
| Anaemia | 1,986 | 2.01.9–2.1 | raised |
| Hyponatraemia | 499 | 1.91.7–2.0 | raised |
| Venous thromboembolism | 1,307 | 1.81.7–1.9 | raised |
| Interstitial lung disease | 487 | 1.51.4–1.7 | raised |
| Arrhythmia / qt | 961 | 1.51.4–1.6 | raised |
| Liver injury | 1,357 | 1.31.3–1.4 | raised |
| Fall / fracture | 1,568 | 1.21.2–1.3 | raised |
| Depression | 1,155 | 1.21.2–1.3 | raised |
| Pancreatitis | 311 | 1.21.0–1.3 | raised |
| Heart failure | 660 | 1.11.0–1.2 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Valacyclovir as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT00306787 — Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults Wit (N=1179, PHASE3; 8 AE terms posted; arms: Famciclovir; Valacyclovir)
- NCT03134196 — Zoster Eye Disease Study (N=527, PHASE4; 45 AE terms posted; arms: Placebo; Masked Oral Valacyclovir 1000 mg Daily)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Fatigue (tiredness) | 4,317 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.776 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.6 | not reported in cached trials |
| Nausea | 3,980 | 1.5 1.5–1.6ROR 1.5 · calibrated p 0.670 | 1.5 EB05 1.5 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.6 | NCT00306787: 18/385 (4.7%) on Valacyclovir |
| Drug ineffective (drug did not work) | 3,963 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.240 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.9 · serious PRR 0.9 | not reported in cached trials |
| Off label use (used outside approved label) | 3,839 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.538 | 1.3 EB05 1.3 · IC025 +0.4 | Reporting / coding artifact | age-adj. PRR 1.3 · serious PRR 1.6 | not reported in cached trials |
| Diarrhoea (diarrhea) | 3,648 | 1.7 1.6–1.8ROR 1.7 · calibrated p 0.794 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.5 · serious PRR 1.6 | NCT00306787: 5/385 (1.3%) on Valacyclovir |
| Headache | 2,965 | 1.4 1.4–1.5ROR 1.4 · calibrated p 0.601 | 1.4 EB05 1.4 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.5 · ♀ 80% (drug 60%) | NCT00306787: 17/385 (4.4%) on Valacyclovir |
| Pyrexia (fever) | 2,753 | 2.4 2.3–2.5ROR 2.4 · calibrated p 0.835 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 2.3 | not reported in cached trials |
| Pain | 2,708 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.529 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.3 | NCT00306787: 4/385 (1.0%) on Valacyclovir |
| Pneumonia (lung infection) | 2,436 | 2.3 2.2–2.4ROR 2.3 · calibrated p 0.898 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 2.0 · serious PRR 1.9 | NCT03134196: 1/261 (0.4%) control (serious AE) |
| Rash | 2,322 | 1.6 1.5–1.7ROR 1.6 · calibrated p 0.724 | 1.6 EB05 1.5 · IC025 +0.6 | Likely indication confounding term in indications; also in warnings | age-adj. PRR 1.6 · serious PRR 1.6 | not reported in cached trials |
| Dizziness | 2,309 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.578 | 1.4 EB05 1.3 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.3 | not reported in cached trials |
| Febrile neutropenia | 2,176 | 10.1 9.7–10.6ROR 10.4 · calibrated p 0.028 ✓ | 9.8 EB05 9.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 10.9 · serious PRR 8.2 · 93% clinician | not reported in cached trials |
| Dyspnoea (shortness of breath) | 2,128 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.393 | 1.1 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | age-adj. PRR 1.0 · serious PRR 1.1 | not reported in cached trials |
| Vomiting | 2,092 | 1.3 1.3–1.4ROR 1.3 · calibrated p 0.540 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.3 | NCT00306787: 3/385 (0.8%) on Valacyclovir |
| Asthenia (weakness) | 1,964 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.695 | 1.6 EB05 1.5 · IC025 +0.6 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.4 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Laryngeal stenosis — n=104, PRR 65.7
- Dyslalia — n=128, PRR 64.0
- Vocal cord dysfunction — n=82, PRR 58.7
- Periorbital pain — n=54, PRR 21.5
- Klebsiella bacteraemia — n=56, PRR 19.1
- Diffuse large b-cell lymphoma refractory — n=54, PRR 18.4
- Herpes ophthalmic — n=70, PRR 16.9
- Cytokine release syndrome — n=956, PRR 15.8
- Post herpetic neuralgia — n=66, PRR 14.3
- Streptococcal bacteraemia — n=49, PRR 14.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Valacyclovir ↔ Acute kidney injury.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Valacyclovir?
In FDA FAERS, the most frequently co-reported reaction terms for Valacyclovir are fatigue, nausea, diarrhoea, headache, pyrexia, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Valacyclovir have an FDA boxed warning?
No. The FDA label retrieved for Valacyclovir has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Valacyclovir causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 26634bf1-c6d8-4d48-9a4e-845c47df07f8, effective 20260604; matched on
openfda.generic_name.exact:"VALACYCLOVIR") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,178 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
VALACYCLOVIR, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.